Masimo and Royal Fornia Electronic Device have signed a worldwide technology licensing agreement to integrate Masimo rainbow SET Pulse CO-Oximetry technology into Royal Fornia's new generation of multiparameter patient monitors.
The integration enables advanced noninvasive blood constituent measurements that help clinicians to detect and treat life-threatening conditions earlier.
Royal Fornia establishes itself as one of the first domestic Chinese medical device manufacturers to commercially incorporate Masimo‘s noninvasive blood constituent measurement capabilities.
Masimo rainbow SET noninvasive and continuous measurements like total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and Pleth Variability Index (PVI), in addition to the ‘gold-standard’ Measure-Through Motion and Low Perfusion performance of Masimo SET oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR) provide detailed physiological data that helps clinicians to more rapidly assess patients and detect adverse conditions much earlier.
With rainbow SET measurements, the ability to noninvasively detect internal bleeding, carbon monoxide poisoning, methemoglobinemia, fluid responsiveness, low perfusion, desaturations, and abnormal pulse rates quickly, easily, and continuously can help save lives and improve patient outcomes.